Ontology highlight
ABSTRACT:
SUBMITTER: Vij R
PROVIDER: S-EPMC5818209 | biostudies-literature | 2012 Sep
REPOSITORIES: biostudies-literature
Vij Ravi R Siegel David S DS Jagannath Sundar S Jakubowiak Andrzej J AJ Stewart Alexander Keith AK McDonagh Kevin K Bahlis Nizar N Belch Andrew A Kunkel Lori A LA Wear Sandra S Wong Alvin F AF Wang Michael M
British journal of haematology 20120730 6
Carfilzomib is a next-generation proteasome inhibitor that selectively and irreversibly binds to its target. In clinical studies, carfilzomib has shown efficacy in patients with relapsed and/or refractory multiple myeloma (MM) and has demonstrated a tolerable safety profile. In this phase 2, open-label, multicentre clinical trial, 35 patients with relapsed and/or refractory MM following 1-3 prior therapies, including at least one bortezomib-based regimen, received carfilzomib 20 mg/m(2) in a twi ...[more]